The clinical significance of circulating microparticles
concerning thrombosis in BCR/ABL1-negative myeloproliferative
neoplasms

J 2021

The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ, Miroslav PENKA et. al.

Základní údaje

Originální název

The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms

Autoři

ASWAD, Mohamed Hussam (760 Sýrie, garant, domácí), Jarmila KISSOVÁ (203 Česká republika, domácí), Petra OVESNÁ (203 Česká republika, domácí), Lucie ŘÍHOVÁ (203 Česká republika, domácí) a Miroslav PENKA (203 Česká republika, domácí)

Vydání

In vivo, Athens, International Institute of Anticancer Research, 2021, 0258-851X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Řecko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.406

Kód RIV

RIV/00216224:14110/21:00122607

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.21873/invivo.12632

UT WoS

000711693300017

Klíčová slova anglicky

Myeloproliferative neoplasm; microparticle; procoagulant activity; thrombosis; anagrelide; hydroxyurea

Štítky

14110212, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 12. 2021 13:12, Mgr. Tereza Miškechová

Anotace

V originále

Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs’ procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.

Citovat

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ a Miroslav PENKA. The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms. In vivo. Athens: International Institute of Anticancer Research, 2021, roč. 35, č. 6, s. 3345-3353. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12632.

@article{1798682,
   author = {Aswad, Mohamed Hussam and Kissová, Jarmila and Ovesná, Petra and Říhová, Lucie and Penka, Miroslav},
   article_location = {Athens},
   article_number = {6},
   doi = {http://dx.doi.org/10.21873/invivo.12632},
   keywords = {Myeloproliferative neoplasm; microparticle; procoagulant activity; thrombosis; anagrelide; hydroxyurea},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms},
   url = {https://iv.iiarjournals.org/content/35/6/3345},
   volume = {35},
   year = {2021}
}

TY  - JOUR
ID  - 1798682
AU  - Aswad, Mohamed Hussam - Kissová, Jarmila - Ovesná, Petra - Říhová, Lucie - Penka, Miroslav
PY  - 2021
TI  - The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms
JF  - In vivo
VL  - 35
IS  - 6
SP  - 3345-3353
EP  - 3345-3353
PB  - International Institute of Anticancer Research
SN  - 0258851X
KW  - Myeloproliferative neoplasm
KW  - microparticle
KW  - procoagulant activity
KW  - thrombosis
KW  - anagrelide
KW  - hydroxyurea
UR  - https://iv.iiarjournals.org/content/35/6/3345
N2  - Background/Aim: This work aimed to prospectively evaluate the clinical significance of circulating microparticles (MPs) in relation to thrombotic risk factors and thrombotic complications in patients with BCR/ABL1-negative myeloproliferative neoplasms (MPN). Patients and Methods: In a cohort of 206 patients with MPN, MPs’ procoagulant activity was measured by the Zymuphen functional assay in 429 samples, while platelet- and erythrocyte-MPs were enumerated by flow cytometry in 558 samples. Results: MPN patients had higher MP levels than the control group. The levels of MPs were higher in male patients, smokers, and those who were older than 60 years, and in the presence of JAK2V617F mutation, history of thrombosis, platelets >400×109/l, hematocrit >45%, or leukocytes >10×109/l. Cytoreductive treatment reduced MP levels, with anagrelide being associated with lower MP levels than hydroxyurea. Conclusion: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
ER  -

ASWAD, Mohamed Hussam, Jarmila KISSOVÁ, Petra OVESNÁ, Lucie ŘÍHOVÁ a Miroslav PENKA. The clinical significance of circulating microparticles concerning thrombosis in BCR/ABL1-negative myeloproliferative neoplasms. \textit{In vivo}. Athens: International Institute of Anticancer Research, 2021, roč.~35, č.~6, s.~3345-3353. ISSN~0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12632.

Podrobný výpis o publikaci